NASDAQ · Biotechnology

Inventiva S.A. (IVA) Stock

$4.47 +1.59% NASDAQ: IVA Healthcare

Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics.

Valuation

MetricValue
Price$4.47
Market Cap$232.36M
P/E Ratio-2.04
P/B Ratio-86.44
P/S Ratio120.05
EPS (TTM)$-1.82
52-Week High$7.98
52-Week Low$2.85
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE1172.41%
ROA-141.93%
ROCE-79.10%
Gross Margin35.07%
Operating Margin-3275.00%
Net Margin-8500.00%
Debt/Equity-2.10
Current Ratio3.16

Annual Financials (USD)

Metric20212022202320242025
Revenue$4.0M$12.0M$17.0M$9.0M$4.0M
Operating Profit$-52.0M$-57.0M$-103.0M$-98.0M$-131.0M
Net Profit$-50.0M$-54.0M$-110.0M$-184.0M$-340.0M
EPS$-1.27$-1.31$-2.43$-3.54$-1.82
Op Margin-1242.6%-468.9%-587.7%-1060.6%-2921.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$122.0M$116.0M$70.0M$119.0M$249.0M
Total Liabilities$33.0M$71.0M$102.0M$226.0M$278.0M
Cash$87.0M$87.0M$27.0M$97.0M$99.0M
Borrowings$10.0M$35.0M$37.0M$54.0M$59.0M

Latest News

Inventiva (IVA) Announces Issuance of New EIB Warrants, Completes EIB Warrant Restructuring Insider Monkey · Jul 15, 2026 Inventiva (ENXTPA:IVA) Puts Its MASH Narrative To The Test After A Recent Rebound Simply Wall St. · Jul 12, 2026 European Equities Traded in the US as American Depositary Receipts Decline Friday MT Newswires · Jul 10, 2026 Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants GlobeNewswire · Jul 9, 2026 European Equities Traded in the US as American Depositary Receipts Rise Thursday MT Newswires · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-48.0M$-45.0M$-82.0M$-86.0M$-101.0M
Investing Cash Flow$-2.0M$8.0M$-8.0M$8.0M$-128.0M
Financing Cash Flow$0$-1.0M$5.0M$68.0M$0
Net Cash Flow$-19.0M$0$-60.0M$70.0M$14.0M
Free Cash Flow$-48.0M$-45.0M$-82.0M$-86.0M$-101.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.15
EV / EBITDA-3.74
FCF Yield-19.58%
Quick Ratio3.16
Interest Coverage-4.06
Return 1Y35.84%
Return 3Y20.27%
Return 5Y-68.85%

Ownership

Insiders Held0.00%
Institutions Held26.12%
Institutions Float Held26.12%
Institutional HolderSharesReport Date
Samsara BioCapital, LLC5,194,8052026-03-31
Caligan Partners, LP4,974,9062026-03-31
Paradigm Biocapital Advisors LP4,000,0002026-03-31
Millennium Management Llc2,987,6132026-03-31
Trails Edge Capital Partners, LP2,657,9972026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AVTX $18.97 +2.87% -2.79 $214.25M 0.00%
CRBU $1.65 +0.61% -1.25 $163.65M 0.00%
ENTA $12.61 -0.94% -6.04 $366.68M 0.00%
EPRX $6.05 +4.13% -5.99 $202.55M 0.00%
GNFTGenfit S.A. $8.95 +4.07% 261.07 $445.68M 0.00%

About Inventiva S.A.

Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.

Inventiva S.A. is headquartered in FR.

Inventiva S.A. (IVA) stock trades at $4.47 with a market capitalization of $232.36M. The stock is valued at a price-to-earnings (P/E) ratio of -2.04, price-to-book of -86.44, price-to-sales of 120.05. Over the past 52 weeks the stock has ranged between $2.85 and $7.98, and currently trades 44.0% below its 52-week high.

On profitability, Inventiva S.A. generates a return on equity (ROE) of 1172.41% — well above the market average, a sign of a high-quality business, return on capital employed of -79.10%, an operating margin of -3275.00%, a net profit margin of -8500.00%.

Official website: www.inventivapharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides